Best Life Sciences Companies in Netherlands
The 754 best Life Sciences companies in Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Crucell.
The 754 Life Sciences companies tracked here for the Netherlands represent $4.1B in disclosed equity funding, ranked by capital raised and recent momentum. No unicorns yet, but the pipeline is real. Kaleido leads the board at $85M, followed by TargED at $46M and Vitestro at $50M, with a cluster of focused plays like TIBEAY Biosciences and Onward rounding out the top tier. Backers including EIC Fund, Europa, and EIT Health have been consistent presences across rounds, which tells you something about where institutional conviction is sitting right now. And PE's growing appetite for life sciences is pushing that conviction further up the risk curve globally, which filters down to markets like this one.
The broader tailwind is hard to ignore. The global sector is tracking toward a ~$167.8B market at a 10.2% CAGR, driven by aging populations and accelerating institutional funding. I'd watch the digital health layer closely too: median install growth across life and health-adjacent apps hit roughly +43% YoY across 15 tracked categories, which signals that patient-facing demand is moving fast. So if you're mapping the Netherlands ecosystem for a deal, a partnership, or just competitive context, the funding spread here reflects a sector that's early, active, and still compressing.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Netherlands
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Leyden Labs Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa | $200M | 12 mo ago | Series B | 80 | Dinko Valerio Co-founder & Executive Chairman | WordPressMySQLPHP+20 | — | — |
| 2 | VectoryTx Developer of therapeutics for neurodegenerative and muscular disorder | $176M | 31 mo ago | Series A | 78 | Sander Van Deventer Chief Executive Officer | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | 3 job openings |
| 3 | NorthSea Therapeutics Developer of structurally engineered fatty acids for metabolic disease treatment | $149M | 54 mo ago | Series C | 4 | David Fraser Co-Founder | — | 4 patents Novel fatty acid derivatives for metabolic and gastrointestinal disease therapies | — |
| 4 | Micreos Develops targeted antibacterial products to replace antibiotics | $109M | 43 mo ago | Series D | 120 | Mark Offerhaus CEO | — | 12 patents Phage-based biocontrol for food safety and animal growth enhancement | — |
| 5 | Vico Developer of RNA modulating therapies for genetic neurological diseases | $103M | 23 mo ago | Series B | 38 | Judith Van Deutekom Scientific Co-Founder and Advisor | WordPressMySQLPHP+16 | — | — |
| 6 | LUMICKS Manufacturer of optical tweezers for single molecule analysis instruments | $93M | 20 mo ago | Series D | 263 | Andrea Candelli Co-Founder | Webflow EcommerceWebflowMemberStack+25 | — | 1 launch |
| 7 | Kaleido Developer of insulin therapy for treating diabetes | $85M | 5 mo ago | Series D | 129 | Tim Oakes Co-Founder & CTO | WordPressMySQLPHP+31 | — | 3 launchs · 1 partnership |
| 8 | Xenikos Developer of toxin-loaded antibodies for T-cell mediated diseases | $82M | 44 mo ago | Series C | 17 | — | — | 3 patents Targeted immunotoxin therapeutics for cancer and infectious disease treatment | — |
| 9 | Varmx Therapeutic proteins to restore blood clotting in bleeding patients | $77M | 36 mo ago | Series B | 10 | Pieter Reitsma Founder | — | — | — |
| 10 | Tagworks Pharmaceuticals Developer of antibody-drug-conjugates for cancer treatment | $65M | 35 mo ago | Series A | 13 | Zach Taylor Co-Founder | WordPressMySQLPHP+22 | 73 patents Patents concentrated in health & consumer products | 1 award |
| 11 | Vitestro Developed AI-based blood drawing robot for clinic use 69Funding top 23%Growth top 28%Moat top 35%Talent top 38% All 9 signals ▾Fundingtop 23% Growthtop 28% Moattop 35% Talenttop 38% Newstop 43% Techtop 44% AItop 45% Marketbottom 46% Globalbottom 36% Funding: Raised $50.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 3 mo ago | Series B | 50 | Toon Overbeeke Co-Founder & CEO | WordPressMySQLPHP+25 | — | — |
| 12 | Avidicure Developer of immunotherapies for cancer therapeutics | $50M | 13 mo ago | Seed | — | Govert Schouten Co-Founder | WordPressMySQLPHP+10 | 8 patents Engineered cytokine/antibody fusion proteins for NK‑cell cancer immunotherapy | — |
| 13 | AkkoLens Developer of Intraocular lenses with shifting optical elements | $48M | 29 mo ago | Series A | — | Michael Rombach Founder & CTO | — | — | — |
| 14 | TargED Developer of biological drugs for the treatment of thrombosis | $46M | 5 mo ago | Series A | 17 | Steven Maat Co-Founder | WordPressMySQLPHP+15 | — | 2 job openings |
| 15 | MicroSure Developer of robotic solutions to advance microsurgery | $43M | 32 mo ago | Series B | 39 | Iwan Vijfeijken CEO | WordPressPleskMySQL+26 | 22 patents Patents concentrated in health & consumer products | — |
| 16 | TIBEAY Biosciences Clinical-stage biopharmaceutical company focused on developing innovative therapies for acute neurological… | $41M | 2 mo ago | Series C | — | Klaas Boer Co-Founder | — | — | 1 expansion |
| 17 | Citryll Targeting neutrophil extracellular traps for autoimmune diseases | $38M | 18 mo ago | Series B | 19 | Eduardo Bravo Chief Executive Officer | WordPressMySQLPHP+20 | 25 patents Anti‑citrullinated histone antibodies for autoimmune disease diagnostics and therapeutics | — |
| 18 | Avanzanite Developer of therapeutics to treat rare diseases | $37M | 6 mo ago | Series A | — | Anant Murthy Co-Founder and Board Advisor | WordPressApple iCloud MailMicrosoft 365+14 | — | 1 job opening · 1 partnership · 1 expansion |
| 19 | ONWARD Developer of a therapeutic device for spinal cord injuries | $35M | 2 mo ago | Public | 100 | Dave Marver CEO | DrupalApple iCloud MailMicrosoft 365+26 | — | — |
| 20 | Salvia BioElectronics Developing bioelectronic solutions for individuals suffering from migraines and other neurological disorders | $34M | 12 mo ago | Series B | — | Wim Pollet Founder & Chief Medical Officer | WebflowGSAPCloudflare Turnstile+12 | 24 patents Implantable neural stimulation devices with flexible electrodes and wireless power management | — |
| 21 | Cradle Provider of chemoproteomics solutions for protein design and development 57AI top 20%Funding top 29%Growth top 35%Talent top 38% All 8 signals ▾AItop 20% Fundingtop 29% Growthtop 35% Talenttop 38% Moattop 42% Techtop 49% Globalbottom 38% Marketbottom 29% AI: Classified as an AI company Funding: Raised $33.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $33M | 18 mo ago | Series B | 14 | Stef Grieken Co-Founder & CEO | Framer SitesApple iCloud MailGoogle Workspace+15 | — | 1 job opening |
| 22 | ScreenPoint Developer of artificial intelligence software for analyzing breast imaging mammograms | $33M | 1 mo ago | Series C | 58 | Michael Brady Co-Founder & Chairman | WordPressMySQLPHP+21 | — | — |
| 23 | Azafaros Developer of small molecule based therapeutics for the treatment of rare metabolic disorders | $28M | 13 mo ago | Series B | 17 | Stefano Portolano CEO | PleskLiteSpeedMicrosoft Advertising+11 | 17 patents Glucosylceramide synthase inhibitor drugs and their crystalline forms for lysosomal storage disease therapy | 1 award |
| 24 | myTomorrows Platform provides access to drugs in development to patients and physicians | $22M | 7 mo ago | Series C | 92 | Ronald Brus Co-Founder & CEO | WagtailWordPressPython+35 | — | 3 job openings |
| 25 | Flindr Developer of precision oncology treatments | $21M | 25 mo ago | Series A | — | Christian Blank Co-Founder | WordPressPleskApple iCloud Mail+27 | — | — |
| 26 | ShanX Medtech Provider of in vitro diagnostic platforms for antibiotic testing | $18M | 5 mo ago | Seed | — | Sophia Shanko CEO | BreakdancewpBakeryWordPress+13 | — | 1 job opening |
| 27 | XiltriX Provider of laboratory management platform | $17M | 18 mo ago | Early Stage | 31 | — | WordPressZohoMySQL+22 | — | 1 partnership |
| 28 | AMT Medical Providing solutions for heart bypass surgery | $12M | 14 mo ago | Series B | 21 | Rutger Tulleken CEO | WordPressMySQLPHP+24 | 6 patents Vascular anastomosis devices and surgical clipping systems for blood vessel connections | — |
| 29 | CardiacBooster Provider of percutaneous left ventricular assist devices | $11M | 10 mo ago | Funding Raised | 18 | — | WordPressMySQLPHP+16 | 23 patents Ventricular assist devices using axial-flow pumps and high-frequency cardiac support technology. | — |
| 30 | DEBx Medical Developer of treatments for chronic wounds | $11M | 19 mo ago | Late Stage | 11 | Alberto Cogo Co-Founder | WordPressApple iCloud MailMySQL+23 | 20 patents Advanced wound debridement and antimicrobial silver-based dressings for tissue removal | 1 launch |
| 31 | Hy2Care Developer of a hydrogel implant for cartilage defect repair 35Talent top 28%Patents top 34%Moat top 37%Funding top 42% All 10 signals ▾Talenttop 28% Patentstop 34% Moattop 37% Fundingtop 42% Innovationtop 44% Growthtop 45% Producttop 46% Globalbottom 40% Techbottom 36% Marketbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Patents: 12 patents matched (strict assignee match) · 9 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $10M | 13 mo ago | Series B | 12 | Chris Cardinaels Co-Founder | PHPNginxjQuery UI+6 | 12 patents Biocompatible hydrogel kits and porous affinity particles for drug delivery and tissue engineering | 1 partnership |
| 32 | Plasmacure Developer of cold plasma solution for the treatment of wounds | $10M | 11 mo ago | Series A | 23 | Bas Zeper Founder and CTO | WordPressMySQLPHP+21 | 11 patents Medical dielectric-barrier plasma therapy devices and their high‑voltage driver/EMC control electronics | 1 job opening |
| 33 | Sensius Developer of a hyperthermia system for cancer treatment. | $8M | 11 mo ago | Series B | — | Paul Den Biggelaar Co-Founder & CEO | — | — | — |
| 34 | Confocal Developer of improved confocal microscope | $6M | 20 mo ago | Series A | 16 | Pim Vos CEO | — | 11 patents Advanced re-scan optical systems for high‑precision confocal microscopy imaging | — |
| 35 | QDI systems Developer of X-ray imaging diagnostic devices for medical applications | $5M | 15 mo ago | Series A | 8 | Artem Shulga Founder & CEO | WordPressMySQLPHP+11 | 4 patents Printable solution-processed nanocrystal inks and conductive polymers for optoelectronic devices | 1 partnership |
| 36 | Pan Cancer T Provider of TCR T-cell therapeutics for the treatment of cancer | $5M | 6 mo ago | Series A | 8 | Reno Debets Founder | WordPressMySQLPHP+13 | — | — |
| 37 | Kaminari Medical Developer of diagnostic solution for vulnerable plaque in the coronary arteries | $4M | 20 mo ago | Series A | 6 | Jeroen Kodde CEO | — | — | 1 job opening |
| 38 | Khondrion Small molecule therapeutics for mitochondrial diseases | $4M | 18 mo ago | Seed | — | Jan Smeitink Founder & CEO | Webflowcore-jsjQuery+11 | 47 patents Small-molecule therapeutics for mitochondrial disorders, CNS migraines/depression, and bone disease | — |
| 39 | Optics11 Life Online e-distributor offering scientific equipment | $4M | 8 mo ago | Series A | 55 | Davide Iannuzzi Co-Founder | Cart FunctionalityWordPressMySQL+31 | — | — |
| 40 | Scinus Developer of closed-system bioreactors for cell therapy production | $3M | 3 mo ago | Series A | 8 | — | — | — | 1 internship · 1 partnership |
| 41 | QurieGen AI-powered drug discovery platform for cancer treatment | $2M | 14 mo ago | Seed | — | Kinga Matula Founder & CEO | — | — | 1 partnership |
| 42 | STIL Orthosis Developer of medical device to alleviate tremors and enhancing voluntary movement | $2M | 12 mo ago | Seed | 7 | IJsbrand Lange Co-Founder & CEO | WordPressMySQLPHP+20 | — | — |
| 43 | DAB Technology solutions provider for accelerated fermentation | $2M | 7 mo ago | Series A | 20 | Kirsten Herben-Steinbusch Founder | SanityRadix UITailwind CSS+18 | — | — |
| 44 | ATRO Medical Developer of a polymer-based meniscus implant | $2M | 3 mo ago | Series A | 9 | Tony Tienen CEO & CMO | PrismicCart FunctionalityNode.js+17 | 8 patents Orthopedic joint implants and meniscus prostheses for knee/stifle stabilization | — |
| 45 | Aiosyn AI-based disease diagnosis tool for providers | $2M | 9 mo ago | Series A | 15 | Jeroen der Laak Co-Founder | WordPressMySQLRedis+28 | — | — |
| 46 | Phlox Therapeutics Developer of gene therapy to cure genetic heart diseases | $2M | 19 mo ago | Seed | 4 | Eva Rooij Co-Founder & CSO | — | — | — |
| 47 | Ansana Developer of sterilization devices for operating rooms and pharma companies | $2M | 8 mo ago | Seed | — | Dominique Surinx CEO | — | — | — |
| 48 | Guideways AI agents automate medtech approval and maintenance processes for faster market access. | $1M | 7 mo ago | Seed | — | Sander Denissen CEO | — | — | — |
| 49 | CryoCloud Provider of cloud-based platform for Cryo-EM data analysis | $541K | 13 mo ago | Seed | — | Robert Englmeier Co-Founder & CEO | SanityNode.jsReact+10 | — | 3 launchs |
| 50 | Respiosa Developer of a surgically implanted solution for tongue-based obstructive sleep apnea | $264K | 6 mo ago | Seed | 1 | — | — | — | — |
Top 12 Life Sciences companies in Netherlands
#1
Public · Eindhoven, North Brabant · founded 2014 · 100 employees$35Mraised▾
Developer of a therapeutic device for spinal cord injuries. The company's ARC therapy is delivered by implantable or external systems as programmed stimulation of the spinal cord that helps restore movement and other functions associated with the spinal cord.
- Apr 2026Post IPO$47.9M
- Oct 2025Post IPO$59.2M
- Nov 2024Grant (prize money)—
- Oct 2024Post IPO$24.3M
#2
Series B · Utrecht, Utrecht · founded 2017 · 50 employees$50Mraised▾
Developed AI-based blood drawing robot for clinic use. The company has developed a medical robotics device that autonomously draws blood from patients. The device has a guided 3D construction with a robotic needle that secures blood collection. It has features for bandage application as well.
- Mar 2026Series B$70M
- Apr 2024Series A$22M
- Mar 2023Grant (prize money)—
- Mar 2023Series A$12.9M
#3
Series C · Nijmegen, Gelderland · founded 2014 · 58 employees$33Mraised▾
Developer of artificial intelligence software for analyzing breast imaging mammograms. This technology integrates with existing medical imaging hardware to assist radiologists in detecting cancer. The software provides automated analysis of breast density and compares current images against previous examinations to identify potential abnormalities. It functions across various imaging systems to support clinical workflows in diagnostic environments.
- Apr 2026Series C$14M
- Apr 2026Grant (prize money)$2M
- Jul 2021Series C$28M
- May 2018Series B$5M
#4
Series C · Nijmegen, Gelderland · founded 2025$41.2Mraised▾
Clinical-stage biopharmaceutical company focused on developing innovative therapies for acute neurological conditions. The company focuses on developing therapies for acute neurological conditions. Its lead compound, Ronopterin, a selective iNOS inhibitor, for severe traumatic brain injury. It aims to reduce secondary brain injury, a condition with no approved pharmacological treatment.
- Apr 2026Series C$41.2M
#5
Series D · Utrecht, Utrecht · founded 2013 · 129 employees$85.3Mraised▾
Hello Kaleido develops an insulin pump for treating diabetes. It is a medical device used for the administration of insulin in the treatment of diabetes mellitus. It uses a Bluetooth channel to connect with the phone which reminds users of insulin administration. The company also provides software for diabetic monitoring.
- Jan 2026Series D$13M
- Sep 2025Series D$85M
- Dec 2021Series C$74M
- Jun 2020Series B$11.3M
#6
Series A · Utrecht, Utrecht · founded 2020 · 17 employees$45.8Mraised▾
Developer of biological drugs for the treatment of thrombosis. The company offers its FDA-approved biological drugs and TargED Targeted Enzyme Delivery system which is a small antibody that can target the specific sites of thrombosis and enable the blood flow to reduce the risk for organ failure is reduced. The company target Thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS) and the lead compound Microlyse is a thrombolytic fusion protein that consisting two subunits i.e a nanobody domain targeting Von Willebrand Factor (VWF) which helps in wound healing also and the protease domain of the plasminogen activator urokinase. It targets the protease domain towards VWF, to active degradation of both VWF and fibrin.
- Dec 2025Series A$25.2M
- Jul 2025Grant (prize money)$2.9M
- Jul 2025Series A$11.8M
- Feb 2022Series A$44.2M
#7
Series B · Amsterdam, North Holland · founded 2020 · 80 employees$200Mraised▾
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa. It develops nasal sprays that stop initial infection, prevent onward transmission, protect broadly against existing and new viruses, and provide universal protection, regardless of an individual’s immune history or comorbidities. The company focuses on harnessing mucosal immunity and broad protection by delivering antibodies directly to the nasal mucosa for immediate anti-viral protection. It develops active substances that target regions that lend themselves to lasting protection against multiple strains and entire virus families.
- Jun 2025Venture Debt$22.8M
- Jan 2025Series B$70M
- Jan 2022Series B$140M
- Mar 2021Series A$47.3M
#8
Series A · Amsterdam, North Holland · founded 2021$37.1Mraised▾
Developer of therapeutics to treat rare diseases. The company focuses on the development of orphan medicine for the treatment of an ultra-rare ophthalmologic disease which includes Acanthamoeba Keratitis (AK) a devastating, highly resistant eye infection.
- Nov 2025Series A$37.1M
#9
Seed · Eindhoven, North Brabant · founded 2019$17.6Mraised▾
Provider of in vitro diagnostic platforms for antibiotic testing. It offers diagnostic solutions to support doctors in making informed treatment decisions for bacterial infections. The flagship product, KAIROS, is a direct from sample device that provides rapid results, enabling healthcare professionals to administer correct antibiotics promptly. It aims to enhance patient outcomes and eliminate the spread of antibiotic resistant bacteria by streamlining the diagnostic process.
- Jan 2026Seed$17.5M
- Jan 2026Grant (prize money)—
- Sep 2023Grant (prize money)$80.9K
#10
Series C · Amsterdam, North Holland · founded 2012 · 92 employees$22.3Mraised▾
myTomorrows offers a platform for early drug access to patients and doctors. The platform connects patients, doctors, and drug companies. It provides information on medical conditions, related clinical trials, and early access programs through its platform. The platform facilitates requests for drugs in development and supplies diagnostic tests.
- Nov 2025Series C$29M
- Jan 2017Series B$10.7M
- Nov 2014Series A$5.6M
- Feb 2014Seed$2.2M
#11
Series A · Bilthoven, Utrecht · founded 2016 · 8 employees$3.5Mraised▾
Developer of closed-system bioreactors for cell therapy production. It provides a cost-effective solution for cultivating clinically relevant cell numbers. The bioreactor system supports both research and development and Good Manufacturing Practice (GMP) processes. Utilizing single-use bags, it offers scalability for large-fold cell expansion. The system is adaptable for both adherent and suspension cell types, using a unique rocking platform to ensure optimal culture conditions. Development included extensive biological process development for various cell types, including mesenchymal stromal cells and induced pluripotent stem cells. The company's technology aims to improve cell therapy and regenerative medicine.
- Mar 2026Series A$3.4M
- Feb 2019Grant (prize money)$36.9K
#12
Series B · Eindhoven, North Brabant · founded 2017$34.3Mraised▾
Developing bioelectronic solutions for individuals suffering from migraines and other neurological disorders. It aim to eenhance the quality of life for migraine sufferers through its neuromodulation therapy. It has developed a paper-thin implant designed to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with migraines.
- May 2025Series B$60M
- Sep 2020Series A$24.8M
- Sep 2020Conventional Debt$5.9M
- Apr 2019Series A$2.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the Netherlands
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 513 Netherlands-affiliated papers.
- Wageningen University & Research116
- Utrecht University59
- Leiden University Medical Center43
- Netherlands Institute of Ecology35
- Erasmus MC30
- Messenger RNA1→6
- Gene3→7
- DNA damage1→5
- Immune system1→5
- DNA repair1→4
- Gene1→5
- Biological pest control1→4
- Population1→4
- Production (economics)1→5
- Public health1→4
- Food security2→4
- Food safety2→4
Where biotechnology is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.